Hims & Hers Health (NYSE:HIMS) COO Michael Chi Sells 14,027 Shares

Posted by Brian Himes on Jun 18th, 2026

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the transaction, the chief operating officer directly owned 432,124 shares in the company, valued at $13,611,906. This trade represents a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Hims & Hers Health Trading Up 1.6%

NYSE:HIMS opened at $31.97 on Thursday. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The firm has a 50-day moving average of $26.11 and a 200-day moving average of $26.61. The company has a market cap of $7.40 billion, a PE ratio of -355.22, a PEG ratio of 59.04 and a beta of 2.37. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company’s revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.20 earnings per share. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.04 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

A number of large investors have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC increased its holdings in Hims & Hers Health by 44.7% during the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after buying an additional 283 shares during the last quarter. W.G. Shaheen & Associates DBA Whitney & Co increased its holdings in Hims & Hers Health by 4.8% during the third quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company’s stock worth $436,000 after buying an additional 350 shares during the last quarter. Sigma Planning Corp increased its holdings in Hims & Hers Health by 1.5% during the first quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock worth $540,000 after buying an additional 388 shares during the last quarter. BAM Wealth Management LLC increased its holdings in Hims & Hers Health by 5.6% during the fourth quarter. BAM Wealth Management LLC now owns 7,380 shares of the company’s stock worth $240,000 after buying an additional 393 shares during the last quarter. Finally, Xponance Inc. increased its holdings in Hims & Hers Health by 1.5% during the third quarter. Xponance Inc. now owns 28,195 shares of the company’s stock worth $1,599,000 after buying an additional 419 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Barclays and other commentators see breakout potential after the Novo Nordisk partnership, citing faster revenue and EBITDA growth in the second half of 2026, helped by weight-loss offerings. HIMS Stock Gained Nearly 6% On Wednesday — Barclays Sees Breakout Potential After Novo Partnership
Positive Sentiment: Investors are also betting on Hims & Hers benefiting from the peptide market and upcoming FDA review, which could open another growth catalyst for the business. HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst
Positive Sentiment: Longer-term bullish coverage argues the Novo deal and international expansion support a path toward management’s 2030 targets of $6.5 billion+ in revenue and $1.3 billion+ in adjusted EBITDA. Hims & Hers: The Bull Case Remains Strong
Neutral Sentiment: The stock has also been supported by discussion that short interest remains elevated, which could leave shares vulnerable to additional short-covering if momentum continues. Hims & Hers Enters A New Phase
Negative Sentiment: Recent insider sales by executives, including COO Michael Chi and insider Irene Becklund, may create some caution, though the filings say the trades were tied to 10b5-1 plans and tax withholding from equity vesting. SEC filing for Michael Chi sale
Negative Sentiment: Despite the upbeat narrative, prior quarterly results were weak, with only 4% revenue growth, declining margins, and a net loss, reminding investors that execution still needs to improve. Hims & Hers: The Bull Case Remains Strong

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Truist Financial increased their target price on shares of Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a report on Friday, May 22nd. JPMorgan Chase & Co. lowered their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Leerink Partners increased their target price on shares of Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a report on Monday, March 16th. Finally, Citigroup increased their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $29.37.

Read Our Latest Analysis on Hims & Hers Health

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.